Invention Grant
US09011867B2 Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)
有权
使用特定肽制备用于治疗未确定意义的单克隆丙种球蛋白病(MGUS)或阴道多发性骨髓瘤(SMM)的药物,
- Patent Title: Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)
- Patent Title (中): 使用特定肽制备用于治疗未确定意义的单克隆丙种球蛋白病(MGUS)或阴道多发性骨髓瘤(SMM)的药物,
-
Application No.: US13147563Application Date: 2010-02-01
-
Publication No.: US09011867B2Publication Date: 2015-04-21
- Inventor: Michael Hundemer , Olaf Christensen
- Applicant: Michael Hundemer , Olaf Christensen
- Applicant Address: DE Heidelberg
- Assignee: Ruprecht-Karls-Universitat Heidelberg
- Current Assignee: Ruprecht-Karls-Universitat Heidelberg
- Current Assignee Address: DE Heidelberg
- Agency: Foley & Lardner LLP
- Priority: EP09152181 20090205
- International Application: PCT/EP2010/000572 WO 20100201
- International Announcement: WO2010/089064 WO 20100812
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K38/03 ; A61K38/04 ; A61K38/08 ; C12N5/0783 ; C12N5/0784

Abstract:
The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). Moreover, the present invention relates to the use of an activated T-cell specifically recognizing the peptide of the present invention or an antigen presenting cell which specifically presents a peptide epitope of the present invention for the preparation of a medicament for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS) or of Smoldering Multiple Myeloma (SMM). The present invention also relates to a method for the ex vivo manufacture of an activated T-cell of the present invention comprising the steps of: a) obtaining T-cells from a sample of a subject suffering from MGUS or SMM, b) contacting said T-cells with a peptide of the present invention, and c) collecting the activated T-cells. The present invention relates further to a method for the ex vivo manufacture of an antigen presenting cell of the present invention comprising the steps of: a) obtaining immature antigen presenting cells from a sample of a subject suffering from MGUS or SMM, b) contacting said immature antigen presenting cells with a peptide of the present invention, and c) collecting the mature antigen presenting cells.
Public/Granted literature
Information query